Literature DB >> 22795790

Resveratrol decreases inflammation and increases utrophin gene expression in the mdx mouse model of Duchenne muscular dystrophy.

Bradley S Gordon1, Diana C Delgado Díaz, Matthew C Kostek.   

Abstract

BACKGROUND & AIMS: Duchenne muscular dystrophy (DMD) is a lethal genetic disease with no cure. Reducing inflammation or increasing utrophin expression can alleviate DMD pathology. Resveratrol can reduce inflammation and activate the utrophin promoter. The aims of this study were to identify an active dose of resveratrol in mdx mice and examine if this dose decreased inflammation and increased utrophin expression.
METHODS: 5-week old mdx mice were given 0, 10, 100, or 500 mg/kg of resveratrol everyday for 10 days. Sirt1 was measured by qRT-PCR and used to determine the most active dose. Muscle inflammation was measured by H&E staining, CD45 and F4/80 immunohistochemistry. IL-6, TNFα, PGC-1α, and utrophin gene expression were measured by qRT-PCR. Utrophin, Sirt1, and PGC-1α protein were quantified by western blot.
RESULTS: The 100 mg/kg dose of resveratrol, the most active dose, increased Sirt1 mRNA 60 ± 10% (p < 0.01), reduced immune cell infiltration 21 ± 6% (H&amp;E) and 42 ± 8% (CD45 immunohistochemistry (p < 0.05)), reduced macrophage infiltration 48 ± 10% (F4/80 immunohistochemistry (p < 0.05)), and increased IL-6, PGC-1α, and utrophin mRNA 247 ± 77%, 27 ± 17%, and 43 ± 23% respectively (p ≤ 0.05). Utrophin, Sirt1, and PGC-1α protein expression did not change.
CONCLUSIONS: Resveratrol may be a therapy for DMD by reducing inflammation.
Copyright © 2012 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22795790     DOI: 10.1016/j.clnu.2012.06.003

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  23 in total

1.  Resveratrol induces expression of the slow, oxidative phenotype in mdx mouse muscle together with enhanced activity of the SIRT1-PGC-1α axis.

Authors:  Vladimir Ljubicic; Matthew Burt; John A Lunde; Bernard J Jasmin
Journal:  Am J Physiol Cell Physiol       Date:  2014-04-23       Impact factor: 4.249

2.  Pharmacological and physiological activation of AMPK improves the spliceopathy in DM1 mouse muscles.

Authors:  Aymeric Ravel-Chapuis; Ali Al-Rewashdy; Guy Bélanger; Bernard J Jasmin
Journal:  Hum Mol Genet       Date:  2018-10-01       Impact factor: 6.150

3.  Combinatorial therapeutic activation with heparin and AICAR stimulates additive effects on utrophin A expression in dystrophic muscles.

Authors:  Christine Péladeau; Aatika Ahmed; Adel Amirouche; Tara E Crawford Parks; Lucas M Bronicki; Vladimir Ljubicic; Jean-Marc Renaud; Bernard J Jasmin
Journal:  Hum Mol Genet       Date:  2015-10-22       Impact factor: 6.150

4.  Oral quercetin administration transiently protects respiratory function in dystrophin-deficient mice.

Authors:  Joshua T Selsby; Christopher G Ballmann; Hannah R Spaulding; Jason W Ross; John C Quindry
Journal:  J Physiol       Date:  2016-05-29       Impact factor: 5.182

Review 5.  Turn up the power - pharmacological activation of mitochondrial biogenesis in mouse models.

Authors:  J C Komen; D R Thorburn
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

6.  Post-natal induction of PGC-1α protects against severe muscle dystrophy independently of utrophin.

Authors:  Mun Chun Chan; Glenn C Rowe; Srilatha Raghuram; Ian S Patten; Caitlin Farrell; Zolt Arany
Journal:  Skelet Muscle       Date:  2014-01-22       Impact factor: 4.912

7.  Improvement of endurance of DMD animal model using natural polyphenols.

Authors:  Clementina Sitzia; Andrea Farini; Federica Colleoni; Francesco Fortunato; Paola Razini; Silvia Erratico; Alessandro Tavelli; Francesco Fabrizi; Marzia Belicchi; Mirella Meregalli; Giacomo Comi; Yvan Torrente
Journal:  Biomed Res Int       Date:  2015-03-15       Impact factor: 3.411

8.  Novel adeno-associated viral vector delivering the utrophin gene regulator jazz counteracts dystrophic pathology in mdx mice.

Authors:  Georgios Strimpakos; Nicoletta Corbi; Cinzia Pisani; Maria Grazia Di Certo; Annalisa Onori; Siro Luvisetto; Cinzia Severini; Francesca Gabanella; Lucia Monaco; Elisabetta Mattei; Claudio Passananti
Journal:  J Cell Physiol       Date:  2014-09       Impact factor: 6.384

Review 9.  SIRT1: A Novel Target for the Treatment of Muscular Dystrophies.

Authors:  Atsushi Kuno; Yoshiyuki Horio
Journal:  Oxid Med Cell Longev       Date:  2016-03-17       Impact factor: 6.543

Review 10.  Resveratrol and Myopathy.

Authors:  Jean Bastin; Fatima Djouadi
Journal:  Nutrients       Date:  2016-04-28       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.